MedTrace Logo

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

NCT02021942 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-02-05

Study results available
· View outcomes & findings →

Summary

This is a monocenter, single-arm, open label phase II trial evaluating the effect of SOM230 LAR in adult patients with inoperable primary thymoma and thymoma metastasis (Masaoka II-IVa). SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks. The purpose of this trial is a proof of concept.

Conditions

  • Primary Inoperable Thymoma
  • Local Recurrent Thymoma

Interventions

DRUG

SOM230 LAR

SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.

Sponsors & Collaborators

  • Crolll Gmbh

    collaborator OTHER

  • Prof. Dr. Berthold Schalke

    lead OTHER

Principal Investigators

  • Berthold Schalke, Prof. Dr. · Professor

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02021942 on ClinicalTrials.gov